80% effective RSV vaccines recommended for older adults and high-risk individuals, coverage low at 24% in winter 2023-2024 season.
Recent research confirms that RSV vaccines are 80% effective in preventing severe illness among adults aged 60 and older, yet only 24% of this demographic received the vaccine during the 2023-2024 winter season. The U.S. Advisory Committee on Immunization Practices now recommends vaccination for all adults 75 and older and those 60 and older with high-risk conditions. New bivalent vaccines may offer extended protection, highlighting the need for improved public awareness about RSV and vaccination.
October 28, 2024
4 Articles